Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance

Table 2 Multivariate analyses for the factors associated with hepatocellular carcinoma and HBsAg seroclearance

Variables	Adjusted HR	95% CI	P-value^*
Development of HCC
Age at HBeAg seroclearance	1.045	0.990–1.103	0.111
Male gender	2.986	0.777–11.472	0.111
Cirrhosis	24.651	3.0128–201.365	0.017
Detectable HBV DNA^† at HBeAg seroclearance	1.228	0.295–5.108	0.778
Elevated ALT^‡ at HBeAg seroclearance	1.625	0.268–9.864	0.598
Tenofovir (versus entecavir)	0.868	0.233–3.237	0.833
Achievement of HBsAg seroclearance
Age at HBeAg seroclearance	1.037	0.995–1.082	0.086
Male gender	0.886	0.306–2.568	0.824
Cirrhosis	1.042	0.351–3.094	0.941
Detectable HBV DNA^† at HBeAg seroclearance	0.980	0.264–3.639	0.976
Elevated ALT^‡ at HBeAg seroclearance	2.169	0.501–9.397	0.301
Tenofovir (versus entecavir)	1.388	0.461–4.178	0.560

^*P-value from logistic regression models
^†The lower limit of detection for HBV DNA is 12 IU/mL
^‡The upper limit of normal ALT level is less than 40 IU/L.
Abbreviations: HR hazard ratio; CI, confidence interval; HCC hepatocellular carcinoma; ALT alanine aminotransferase; HBV hepatitis B virus; HBeAg Hepatitis B e antigen; HBsAg Hepatitis B s antigen

ISSN: 1471-230X